Table 2.
Incidence rates of HZ (per 1000 persons - year) by age groups and IC condition in the Valencia Region in 2009–2014
| IC condition | Incidence rate of HZ per 1000 PY (95% CI) | |||||||
|---|---|---|---|---|---|---|---|---|
| 18–29 | 30–39 | 40–49 | 50–59 | 60–69 | 70–79 | ≥ 80 | Overall | |
| Population | 2.32 (2.27–2.37) | 2.46 (2.42–2.51) | 2.93 (2.88–2.98) | 5.88 (5.80–5.96) | 8.63 (8.53–8.74) | 9.82 (9.69–9.95) | 10 (9.83–10.16) | 5.02 (4.99–5.04) |
| IC-free cohort | 2.26 (2.21–2.31) | 2.36 (2.32–2.41) | 2.75 (2.70–2.80) | 5.52 (5.44–5.61) | 8.12 (8.01–8.23) | 9.29 (9.15–9.43) | 9.54 (9.36–9.71) | 4.64 (4.61–4.67) |
| IC-cohort | 3.61 (3.33–3.91) | 4.28 (4.02–4.54) | 5.52 (5.26–5.79) | 9.55 (9.22–9.90) | 12.42 (12.05–12.80) | 12.93 (12.54–13.33) | 12.69 (12.21–13.29) | 9.15 (9.02–9.29) |
| HSCT | 42.37 (21.89–74.02) | 38.94 (24.11–59.53) | 50.13 (35.81–68.26) | 69.24 (54.08–87.33) | 61.82 (47.5–79.1) | 51.99 (24.93–95.61) | 0 | 56.07 (48.86–64.04) |
| SOT | 6 (3.61–9.37) | 6.23 (4.58–8.29) | 7.31 (5.83–9.05) | 14.89 (12.87–17.14) | 17.02 (14.93–19.32) | 14.21 (12.06–16.62) | 17.26 (13.83–21.29) | 12.65 (11.8–13.54) |
| HN | 4.96 (4.1–5.94) | 4.53 (3.77–5.41) | 5.86 (4.97–6.87) | 13.95 (12.5–15.52) | 18.03 (16.46–19.7) | 20.06 (18.37–21.85) | 18.44 (16.46–20.6) | 11.99 (11.48–12.52) |
| SON | 3.87 (2.59–5.56) | 4.94 (4.1–5.9) | 5.84 (5.25–6.49) | 10.24 (9.66–10.85) | 12.27 (11.76–12.80) | 12.12 (11.64–12.62) | 12 (11.43–12.59) | 10.97 (10.73–11.22) |
| NEOPLASIAS | 4.64 (3.92–5.45) | 4.71 (4.14–5.33) | 5.86 (5.36–6.40) | 10.70 (10.16–11.26) | 12.86 (12.40–13.40) | 12.91 (12.43–13.39) | 12.53 (11.98–13.11) | 11.01 (10.79–11.23) |
| HIV | 11.9 (8.08–16.89) | 12.34 (10.28–14.7) | 13.44 (11.96–15.06) | 12.8 (10.65–15.27) | 13.99 (9.9–19.2) | 11.38 (5.68–20.36) | 3.87 (0.1–21.56) | 12.94 (11.95–13.99) |
| AUTOIMMUNE | 3.35 (3.05–3.67) | 3.9 (3.62–4.2) | 4.7 (4.4–5.01) | 8.97 (8.54–9.42) | 12.41 (11.87–12.98) | 13.98 (13.32–14.66) | 13.34 (12.45–14.27) | 7.88 (7.71–8.05) |
| RA | 4.19 (2.74–6.14) | 5.34 (4.1–6.83) | 6.03 (5.04–7.16) | 10.22 (9.11–11.42) | 13.88 (12.65–15.2) | 14.3 (13–15.7) | 13.71 (12.05–15.53) | 11.05 (10.52–11.59) |
| SLE | 9.76 (5.33–16.37) | 8.62 (5.93–12.1) | 8.37 (6.01–11.36) | 17.2 (13.27–21.92) | 20.37 (15.07–26.94) | 21.8 (14.81–30.94) | 19.63 (10.73–32.93) | 13.36 (11.75–15.14) |
| IBD | 4.83 (3.66–6.25) | 4.6 (3.78–5.56) | 5.16 (4.31–6.12) | 9.65 (8.3–11.16) | 13.4 (11.59–15.4) | 12.97 (11.01–15.18) | 16.21 (13.21–19.67) | 8.29 (7.77–8.84) |
| PSORIASIS | 2.97 (2.63–3.34) | 3.37 (3.03–3.74) | 3.74 (3.37–4.14) | 7.55 (6.98–8.16) | 10.39 (9.65–11.16) | 12.4 (11.41–13.44) | 11.11 (9.72–12.64) | 6.13 (5.92–6.34) |
| MS | 5.48 (2.51–10.4) | 4.39 (2.75–6.64) | 4.13 (2.67–6.09) | 7.22 (4.87–10.31) | 12.34 (8.33–17.62) | 10.96 (5.47–19.62) | 12.15 (2.51–35.51) | 6.33 (5.29–7.51) |
| AT | 1.35 (0.37–3.47) | 2.07 (1.1–3.55) | 4.21 (2.88–5.94) | 10 (7.9–12.5) | 11.06 (8.42–14.27) | 13.56 (9.64–18.54) | 17.97 (10.82–28.06) | 7.19 (6.31–8.15) |
CI Confidence interval, IC immunocompromised, HSCT haematopoietic stem cell transplant, SOT solid organ transplantation, HN haematological neoplasia, SON solid organ neoplasia, NEOPLASIAS neoplasias overall, HIV human immunodeficiency virus, AUTOIMMUNE RA rheumatoid arthritis, SLE systemic lupus erythematosus, IBD Inflammatory bowel disease, MS multiple sclerosis, AT autoimmune thyroiditis, AUTOIMMUNE immunodeficiency disorders and autoimmune diseases overall (See supplementary Table 1)